Abcam, ab144653, JZL 195 hydrochloride, FAAH/MAGL inhibitor

Size: 10mg / 50mg
MW 433.5 Da, Purity >99%. Potent dual FAAH/MAGL inhibitor. Shows analgesic effects in vivo. Centrally active. Blood-brain barrier permeable.
Key facts
CAS number:1210004-12-8,
Purity:>99%,
Form:SolidSee storage information,
Molecular weight:433.5 Da,
Molecular formula:C24H23N3O5,
PubChem:46232606,
Nature:Synthetic,
Solubility:Soluble in DMSO to 100 mM,
Biochemical name:(4-Nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate,
Biological description:Potent dual FAAH/MAGL inhibitor. Shows analgesic effects in vivo. Centrally active. Blood-brain barrier permeable.,
Canonical smiles:C1CN(CCN1CC2=CC(=CC=C2)OC3=CC=CC=C3)C(=O)OC4=CC=C(C=C4)[N+](=O)[O-],
InChi:InChI=1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2,
InChiKey:QNYRAEKLMNDRFY-UHFFFAOYSA-N,
IUPAC Name:(4-nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store under desiccating conditions

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Monoacylglycerol lipase (MGL) also known as FAAH1 or ABHD6 breaks down monoacylglycerols into free fatty acids and glycerol. This enzyme specifically hydrolyzes the monoacylglycerol 2-arachidonoylglycerol an important precursor in lipid signaling pathways. MGL weighs approximately 33 kDa and is highly expressed in the brain liver and adipose tissues. Its activity directly affects the cellular levels of endocannabinoids and plays a significant role in lipid metabolism.
Biological function summary
The enzyme influences cannabinoid and eicosanoid pathways impacting various physiological systems. MGL operates as a single enzyme but works alongside other lipid enzymes in a complex cellular environment to regulate endocannabinoid signaling. It controls the termination of endocannabinoid signals which are involved in pain mood and appetite regulation. The coordination of its activity with enzymes like FAAH/MGL dual inhibitor provides a check on the metabolism of endocannabinoids maintaining balance within the system.
Pathways
The enzyme is an important player in the endocannabinoid and prostaglandin pathways. Its function relates significantly to the catabolic control of 2-arachidonoylglycerol a process interlinked with FAAH enzyme activity. MGL manages the breakdown while FAAH and MAGL inhibitors can modulate this process affecting the production of pro-inflammatory eicosanoids. These pathways contribute to a wide range of physiological processes including pain response and inflammation management.
The target associates with neurodegenerative diseases and inflammation-related conditions. Altered MGL activity links to disorders like Alzheimer's disease where the enzyme's dysregulation can exacerbate neuroinflammation due to unchecked pro-inflammatory lipid mediators. The enzyme is also involved in obesity-related disorders through its impact on lipid accumulation. Disruption in the balance of MGL and related enzymes affects the endocannabinoid system triggering pathways that contribute to these conditions.